NCOA5

NCOA5 (also called CIA) is a bifunctional nuclear receptor coregulator that modulates transcription at multiple promoters and functions as an upstream suppressor of IL-6-driven inflammation and tumorigenesis. It was originally identified as a coactivator of estrogen receptor α (ERα) that enhances ERα-dependent transcription via a novel overlapping LxxLL/ΦxxΦΦ motif independently of the AF-2 domain, yet it also cooperates with TIP30 to repress ERα-mediated c-myc transcription at the c-myc promoter (PMID:11113208, PMID:15073177). In macrophages, NCOA5 acts as an LXR corepressor recruited downstream of TLR3 signaling to suppress ABCA1 expression and cholesterol efflux (PMID:25755249). Haploinsufficiency of Ncoa5 in mice causes elevated IL-6 expression leading to hepatic steatosis, glucose intolerance, male-specific hepatocellular carcinoma, and epididymal dysfunction with male infertility — phenotypes partially rescued by genetic reduction of IL-6 or its downstream effector p21^{WAF1/CIP1} — while in cancer cell lines NCOA5 promotes proliferation and epithelial-to-mesenchymal transition through PI3K/AKT pathway activation (PMID:24332041, PMID:31664153, PMID:32203160, PMID:29296214).

1. 2001 High

   The discovery that CIA/NCOA5 interacts with ERα independently of the AF-2 domain and enhances estradiol-dependent transcription via a novel overlapping LxxLL/ΦxxΦΦ motif established it as a new class of nuclear receptor coactivator with an unconventional mode of receptor recognition.

   Evidence Yeast two-hybrid screen, in vitro binding, transactivation assays, and motif mutagenesis in mammalian cells

   PMID:11113208

   Open questions at the time

   • No endogenous target gene identified at this stage
   • Whether the AF-2-independent mechanism operates in vivo was untested
   • Corepressor potential was not explored
2. 2004 High

   Demonstrating that NCOA5 is recruited to the endogenous c-myc promoter by liganded ERα and cooperates with TIP30 to repress c-myc transcription resolved the paradox that a coactivator could also function as a gene-specific corepressor, revealing context-dependent bifunctionality.

   Evidence ChIP at the c-myc promoter, co-immunoprecipitation of CIA–TIP30, and knockdown/overexpression in cells and TIP30 knockout mouse mammary glands

   PMID:15073177

   Open questions at the time

   • Whether repression involves specific chromatin remodeling or histone modifications was not addressed
   • Generalizability of the corepressor function to other ERα target genes was untested
3. 2007 Medium

   Identification of NCOA5 in a nuclear complex with ZAP3, SAM68, hnRNP-G, and NF110/45 in a nucleic acid-dependent manner suggested additional roles beyond nuclear receptor coregulation, potentially linking it to RNA processing.

   Evidence Co-immunoprecipitation and proteomic analysis of ZAP3-associated complex with nucleic acid digestion controls

   PMID:17890166

   Open questions at the time

   • No functional consequence of NCOA5 participation in this complex was demonstrated
   • Single Co-IP-based identification without reciprocal validation for NCOA5 specifically
   • Whether the interaction is RNA- or DNA-dependent was not fully resolved
4. 2013 High

   The finding that Ncoa5 haploinsufficiency causes male-specific hepatocellular carcinoma preceded by IL-6 overexpression, glucose intolerance, and steatosis — with IL-6 blockade averting metabolic and partly tumor phenotypes — established NCOA5 as a tumor suppressor that restrains IL-6 signaling to link metabolic homeostasis and liver cancer.

   Evidence Ncoa5 heterozygous knockout mouse model with IL-6 neutralizing antibody rescue, histopathology, and metabolic phenotyping

   PMID:24332041

   Open questions at the time

   • Direct transcriptional mechanism by which NCOA5 suppresses IL-6 expression was not identified
   • Why the phenotype is male-specific was unexplained
   • Cell-type-specific contributions (hepatocyte vs. immune cell) were unresolved
5. 2015 High

   Showing that NCOA5 functions as an LXR corepressor recruited to the Abca1 promoter downstream of TLR3 signaling to suppress cholesterol efflux in macrophages expanded its corepressor role beyond ERα to a second nuclear receptor and linked it to innate immune regulation of lipid metabolism.

   Evidence Promoter enrichment-quantitative mass spectrometry, ChIP, siRNA knockdown, and cholesterol efflux assays in macrophages

   PMID:25755249

   Open questions at the time

   • Whether NCOA5 represses other LXR target genes was not explored
   • The corepressor complex composition at the Abca1 promoter beyond NCOA5 was incompletely defined
   • In vivo relevance for atherosclerosis was not tested
6. 2017 Medium

   Demonstration that NCOA5 overexpression promotes colorectal cancer cell proliferation and invasion via PI3K/AKT activation, with pharmacological PI3K inhibition abolishing these effects, provided a defined signaling axis through which NCOA5 drives oncogenic phenotypes in an epithelial cancer context.

   Evidence NCOA5 knockdown/overexpression in CRC cell lines, LY294002 treatment, xenograft model, and Western blot for downstream effectors

   PMID:29296214

   Open questions at the time

   • How NCOA5 activates PI3K/AKT was not determined (direct vs. transcriptional)
   • Apparent contradiction with tumor suppressor role in liver was not reconciled
   • Single-lab finding without independent replication
7. 2018 Medium

   CRISPR-mediated knockout of NCOA5 in HCC cells suppressed proliferation, migration, and EMT, providing cell-autonomous evidence that NCOA5 sustains the mesenchymal phenotype in liver cancer cells.

   Evidence CRISPR/Cas9 knockout in HCC cell lines with proliferation, migration, and EMT marker analysis

   PMID:29626478

   Open questions at the time

   • Downstream transcriptional targets mediating EMT were not identified
   • Whether the pro-tumorigenic cell-autonomous role conflicts with the in vivo tumor suppressor phenotype was not addressed
   • Single-lab study in established cell lines
8. 2019 High

   Establishing that Ncoa5 haploinsufficiency causes male infertility through elevated epididymal IL-6, rescuable by Il-6 heterozygous deletion, generalized the NCOA5–IL-6 regulatory axis beyond the liver and demonstrated its importance in reproductive biology.

   Evidence Ncoa5+/− mouse model, Il-6 heterozygous epistasis, immunohistochemistry, and sperm motility assays

   PMID:31664153

   Open questions at the time

   • Whether NCOA5 directly regulates Il-6 transcription in epididymal cells was not shown
   • The molecular basis of male specificity remained unresolved
9. 2020 High

   Identification of p21^{WAF1/CIP1} as an essential downstream effector of NCOA5 deficiency in the protumorigenic liver microenvironment — with p21 heterozygous deletion and metformin both reversing immune niche changes and reducing HCC — defined a specific molecular mediator connecting NCOA5 loss to MDSC expansion, M2 polarization, and hepatocarcinogenesis.

   Evidence Ncoa5+/− mice crossed with p21+/− mice, flow cytometry, transcriptomics, and metformin intervention

   PMID:32203160

   Open questions at the time

   • How NCOA5 deficiency induces p21 overexpression was not determined
   • Whether metformin acts through NCOA5/p21 axis specifically or through general AMPK activation was unclear
   • Human relevance of the NCOA5–p21–immune niche axis was not validated
10. 2020 Medium

    Showing that NCOA5 binds the mTOR promoter and is required for amino acid-induced PI3K-mediated mTOR activation in mammary epithelial cells provided a direct transcriptional mechanism linking NCOA5 to nutrient sensing and mTOR regulation.

    Evidence ChIP-qPCR at mTOR promoter, NCOA5 overexpression/knockdown, PI3K inhibitor treatment in bovine mammary epithelial cells

    PMID:32736675

    Open questions at the time

    • Demonstrated only in bovine cells; transferability to human systems not established
    • Whether mTOR promoter binding occurs through a nuclear receptor or independently was not tested
    • Single-lab study

• The direct transcriptional mechanism by which NCOA5 suppresses IL-6 expression, the molecular basis of male-specific phenotypes, and whether NCOA5 functions as a context-dependent oncogene versus tumor suppressor in different tissues remain unresolved.
• No NCOA5 structural model exists to explain how it switches between coactivator and corepressor modes
• Direct DNA- or chromatin-binding specificity of NCOA5 at the IL-6 locus is uncharacterized
• Reconciliation of tumor-promoting (CRC/HCC cell-autonomous) and tumor-suppressive (Ncoa5+/− mouse) roles lacks a unifying model